重组人血管内皮抑素联合吉非替尼一线治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的疗效及安全性  

Effect and safety of recombinant human endostatin combined with gefitinib in the first-line treatment of epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer

作　　者：吕峰 路世鹏 郭海华 LYU Feng;LU Shipeng;GUO Haihua(Department of Thoracic Surgery,the Second Affiliated Hospital of Air Force Medical University of PLA,Xi’an 710000,Shaanxi,China)

机构地区：[1]解放军空军军医大学第二附属医院胸腔外科,西安710000

出　　处：《癌症进展》2021年第18期1892-1895,共4页Oncology Progress

摘　　要：目的探讨重组人血管内皮抑素联合吉非替尼一线治疗表皮生长因子受体(EGFR)突变阳性晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法依据治疗方案将100例EGFR突变阳性晚期NSCLC患者分为研究组和对照组,每组50例,对照组患者给予吉非替尼治疗,研究组患者给予重组人血管内皮抑素联合吉非替尼治疗。比较两组患者的临床疗效、生活质量、不良反应和随访3年的生存情况。结果研究组患者的客观缓解率、疾病控制率分别为82.00%、94.00%,均高于对照组患者的60.00%、80.00%(P﹤0.05)。治疗后,两组患者的卡氏功能状态(KPS)评分均明显高于本组治疗前(P﹤0.01),且研究组患者的KPS评分明显高于对照组(P﹤0.01)。两组患者胃肠道反应、皮肤反应、肝肾反应和血液系统反应发生率均无明显差异(P﹥0.05)。随访3年,研究组患者的3年累积总生存率为16.00%,明显高于对照组患者的2.00%(P﹤0.01)。结论重组人血管内皮抑素联合吉非替尼一线治疗EGFR突变阳性晚期NSCLC的疗效确切,能有效提高客观缓解率和疾病控制率,延长患者生存时间,改善生活质量,且不良反应少。Objective To explore the efficacy and safety of recombinant human endostatin combined with gefitinib in the first-line treatment of epidermal growth factor receptor(EGFR)mutation-positive advanced non-small cell lung cancer(NSCLC).Method A total of 100 patients with EGFR mutation-positive advanced NSCLC were divided into study group and control group,with 50 cases in each group according to the treatment plan.Patients in the control group were treated with gefitinib,and patients in the study group were treated with gefitinib combined with recombinant human endostatin.The clinical efficacy,quality of life,adverse events,and overall survival of the two groups of patients were compared.Result The objective response rate and disease control rate of the study group were 82.00% and 94.00%,respectively,which were higher than those of the control group of 60.00% and 80.00%(P<0.05).After the treatment,the Karnofsky performance status(KPS)scores of the two groups of patients were significantly higher than those of before treatment(P<0.01),and the KPS scores of the patients in the study group were significantly higher than those of the control group(P<0.01).There were no significant differences in the incidence of gastrointestinal events,skin events,hepatorenal events,and blood system events between the two groups(P>0.05).After 3 years of follow-up,the 3-year cumulative overall survival rate of patients in the study group was 16.00%,which was significantly higher than the 2.00% of patients in the control group(P<0.01).Conclusion Recombinant human endostatin combined with gefitinib has a definite effect in the first-line treatment of EGFR mutation-positive advanced NSCLC,which can effectively improve the objective response rate and disease control rate,prolong patients’survival,improve their quality of life with fewer adverse events.

关 键 词：吉非替尼 重组人血管内皮抑素 表皮生长因子受体 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]